文献速递骨质疏松与代谢性骨病

年度唑来膦酸对绝经后骨质疏松女性3年腹主动脉钙化进展的影响:HORIZON关键骨折试验结果

Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial.
PubMed 文献 · Osteoporos Int · 2020-05-02

该研究为HORIZON关键骨折试验的事后分析,纳入502例绝经后骨质疏松女性(平均年龄72.5岁),其中234例接受唑来膦酸、268例接受安慰剂。通过基线和3年脊柱X线评估腹主动脉钙化(AAC)评分,发现两组AAC进展比例相似(唑来膦酸组29% vs 安慰剂组31%,P=0.64),提示年度唑来膦酸未影响AAC进展。

要点

  • 年度唑来膦酸未改变绝经后骨质疏松女性3年腹主动脉钙化进展比例。
  • 两组AAC进展比例分别为29%和31%,差异无统计学意义(P=0.64)。
  • 骨密度变化与AAC评分变化无相关性。

核心结论

  • 年度唑来膦酸未影响绝经后骨质疏松女性3年内腹主动脉钙化的进展。

研究设计与样本

  • HORIZON关键骨折试验的事后分析,纳入502例绝经后骨质疏松女性,平均年龄72.5岁,234例接受唑来膦酸、268例接受安慰剂。
  • AAC评分(范围0-8)通过基线和3年时配对的脊柱X线评估,AAC进展定义为评分任何增加。

主要发现

  • 基线时292例(58.2%)存在AAC(评分>0),两组AAC评分相似(中位数[四分位距]均为1[0-2],P=0.98)。
  • 3年内两组AAC进展比例相似:唑来膦酸组29%,安慰剂组31%(P=0.64)。
  • 骨密度变化与AAC评分变化无相关性。

关键数值与推荐

  • AAC进展定义为AAC评分(范围0-8)任何增加。
  • AAC进展比例唑来膦酸组29% vs 安慰剂组31%,P=0.64。

临床怎么用

  • 对于绝经后骨质疏松女性,年度唑来膦酸治疗3年未显示对腹主动脉钙化进展有影响,临床决策时无需以改善血管钙化为目的使用该药。

局限性

  • 本研究为事后分析,原始试验主要终点并非AAC进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study evaluated whether zoledronic acid (ZA) inhibited the progression of abdominal aortic calcification (AAC) over 3 years in 502 postmenopausal women with osteoporosis. AAC progressed in a similar proportion of participants in the ZA (29%) and placebo (31%) groups, suggesting no effect of ZA on AAC progression. INTRODUCTION: Bisphosphonate use is associated with reduced risk of all-cause mortality and cardiovascular events. The underlying mechanisms are uncertain but may include effects on vascular calcification. This study aimed to evaluate the effect of zoledronic acid (ZA) on abdominal aortic calcification (AAC) in postmenopausal women with osteoporosis. METHODS: This was a post hoc analysis of the HORIZON Pivotal Fracture Trial that included 502 postmenopausal women (mean age 72.5 years) with osteoporosis (234 received ZA and 268 placebo). AAC scores (range, 0-8) were assessed from paired spine X-rays at baseline and after 3 years. Progression of AAC was defined as any increase in AAC score. The association between change in hip and femoral neck bone mineral density and change in AAC score was also assessed. RESULTS: At baseline, 292 (58.2%) participants had AAC (i.e., AAC score > 0), with AAC scores similar in the two intervention groups (median [interquartile range], 1 [0 to 2] for both; p = 0.98). Over 3 years, AAC progressed in a similar proportion of participants in both groups (ZA 29% and placebo 31%; p = 0.64). Change in bone mineral density and change in AAC score were not correlated. CONCLUSION: Once-yearly zoledronic acid did not affect progression of AAC over 3 years in postmenopausal women with osteoporosis. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00049829.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cai G, Keen HI, Host LV, et al. Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int. 2020. PMID: 32361951. doi:10.1007/s00198-020-05430-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。